AstraZeneca forecasts 12–15% 2026 sales growth after Q4 beat estimates
AstraZeneca delivered Q4 revenue of $11.5 billion, up 10% at constant exchange rates, with adjusted EPS of $1.47, beating consensus by $0.02. It forecasts 2026 sales growth of 12–15% at CER and core profit growth of 15–18%, targeting operating margins around 38–40%.
1. Q4 Financial Results
AstraZeneca reported Q4 revenue of $11.5 billion, a 10% increase at constant exchange rates, led by strong oncology and immunology sales. Adjusted EPS reached $1.47, surpassing analyst expectations by $0.02, supported by favorable product mix and operational efficiencies.
2. 2026 Growth Forecast
The company projects 2026 sales growth of 12–15% at constant exchange rates and core profit growth of 15–18%, reflecting continued momentum in key therapeutic areas. Management expects operating margins to expand to approximately 38–40% as investments stabilize and cost synergies unfold.
3. Key Drivers and Outlook
Growth will be driven by late-stage pipeline launches and increased uptake of breakthrough therapies in oncology and respiratory care. Currency headwinds are expected to be modest, while R&D and SG&A investments remain focused on high-potential programs and margin enhancement.